Patents by Inventor John Yanni

John Yanni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE
    Publication number: 20110257137
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.
    Type: Application
    Filed: March 10, 2011
    Publication date: October 20, 2011
    Applicant: KALYPSYS, INC.
    Inventors: Allen Borchardt, Robert Davis, Clay Beauregard, Daniel Becker, Daniel Gamache, Stewart A. Noble, Mark Hellberg, Peter Klimko, Zhihai Qiu, Joseph Payne, John Yanni
  • HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE
    Publication number: 20110237599
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.
    Type: Application
    Filed: March 9, 2011
    Publication date: September 29, 2011
    Applicant: Kalypsys, Inc.
    Inventors: Allen Borchardt, Robert Davis, Clay Beauregard, Daniel Gamache, Mark Hellberg, Peter Klimko, John Yanni
  • USE OF OCULOSURFACE SELECTIVE GLUCOCORTICOID IN THE TREATMENT OF DRY EYE
    Publication number: 20080096852
    Abstract: Topical ophthalmic compositions and methods for treating dry eye are described. The compositions and methods of the invention are based on the finding that the oculosurface selective properties of the glucocorticoid rimexolone make this anti-inflammatory agent particularly well-suited for treating dry eye. As a result of the limited ability of rimexolone to penetrate the cornea, a high portion of the drug remains on the surface of the eye, which is the primary locus of the inflammatory conditions associated with dry eye. This enables a very low concentration of drug to be utilized, which in turn reduces the potential for elevations of intraocular pressure and cataract formation.
    Type: Application
    Filed: October 26, 2007
    Publication date: April 24, 2008
    Applicant: Alcon,Inc.
    Inventors: John YANNI, Daniel Gamache, Steven Miller, Ernesto Castillo
  • RNAI-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS
    Publication number: 20070281901
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
    Type: Application
    Filed: May 17, 2007
    Publication date: December 6, 2007
    Applicant: Alcon Manufacturing, Ltd.
    Inventors: John Yanni, Jon Chatterton, Diane Senchyna, Daniel Gamache, Steven Miller
  • Treatment of dry eye restoring 15-lipoxygenase activity to ocular surface cells
    Publication number: 20060217325
    Abstract: The present invention provides compositions comprising the 15-lipoxygenase-1 (15-LO-1) or 15-lipoxyngenase-2 (15-LO-2) gene such that 15-LO-1 or 15-LO-2 protein expression is replaced or replenished in the ocular surface epithelium of post-menopausal women suffering from dry eye. Thus, methods for treatment of dry eye in postmenopausal women are further provided.
    Type: Application
    Filed: October 17, 2003
    Publication date: September 28, 2006
    Applicant: Alcon, Inc.
    Inventors: John Yanni, Daniel Gamache, Steven Miller
  • Method of treating dry eye disorders using 13(S)-HODE and its analogs
    Publication number: 20060128803
    Abstract: The topical use of 13(S)-HODE and analogs are disclosed for the treatment of dry eye disorders.
    Type: Application
    Filed: December 14, 2005
    Publication date: June 15, 2006
    Inventors: Peter Klimko, Daniel Gamache, Gustav Graff, Mark Hellberg, John Falck, John Yanni
  • Methods for treating dry eye
    Publication number: 20060069075
    Abstract: Methods of treating dry eye by administering fixed combinations of MUC-1 secretagogues, such as HETE derivatives, and anti-inflammatory steroids are disclosed.
    Type: Application
    Filed: November 15, 2005
    Publication date: March 30, 2006
    Inventors: Daniel Gamache, John Yanni, Barry Van Duzee
  • Use of oculosurface selective glucocorticoid in the treatment of dry eye
    Publication number: 20060058277
    Abstract: Topical ophthalmic compositions and methods for treating dry eye are described. The compositions and methods of the invention are based on the finding that the oculosurface selective properties of the glucocorticoid rimexolone make this anti-inflammatory agent particularly well-suited for treating dry eye. As a result of the limited ability of rimexolone to penetrate the cornea, a high portion of the drug remains on the surface of the eye, which is the primary locus of the inflammatory conditions associated with dry eye. This enables a very low concentration of drug to be utilized, which in turn reduces the potential for elevations of intraocular pressure and cataract formation.
    Type: Application
    Filed: October 14, 2005
    Publication date: March 16, 2006
    Inventors: John Yanni, Daniel Gamache, Steven Miller, Ernesto Castillo
  • Method of treating vascular endothelial growth factor mediated vascular disorders
    Publication number: 20050143468
    Abstract: The use of amfenac and derivatives, including nepafenac, to treat vascular endothelial growth factor mediated vascular disorders.
    Type: Application
    Filed: April 16, 2003
    Publication date: June 30, 2005
    Inventors: David Bingaman, Michael Kapin, Daniel Gamache, Gustav Graff, John Yanni